Sarah L. Chamlin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sarah L. Chamlin has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Anthony J. Mancini
Ann & Robert H. Lurie Children's Hospital of Chicago/Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
6 shared publications - Ilona J. Frieden
Department of Dermatology University of California San Francisco California USA
5 shared publications Mary L. Williams
5 shared publicationsMary-Margaret Chren
Department of Dermatology, University of California at San Francisco, 4150 Clement Street 151R, San Francisco, CA 94121, USA
5 shared publicationsDavid Cella
3 shared publicationsJin-Shei Lai
2 shared publications
Latest Publications
- 23 July 2015
- Published by Wiley in Pediatric Dermatology
- Vol. 32 (5) , e200-e203
Infantile Fistula‐in‐Ano: A Report of Two Patients and Review for Dermatologists
Infantile fistula‐in‐ano is a well‐known entity to pediatric surgeons but less recognized by dermatologists. Because these patients may initially present to a dermatologist or pediatric dermatologist, familiarity with the presentation is important. We present two infants with fistula‐in‐ano and review the literature on this condition.
- 23 July 2015
- Published by Wiley in Pediatric Dermatology
- Vol. 32 (5) , e200-e203
Infantile Fistula‐in‐Ano: A Report of Two Patients and Review for Dermatologists
Infantile fistula‐in‐ano is a well‐known entity to pediatric surgeons but less recognized by dermatologists. Because these patients may initially present to a dermatologist or pediatric dermatologist, familiarity with the presentation is important. We present two infants with fistula‐in‐ano and review the literature on this condition.
- 7 November 2012
- Published by Wiley in Pediatric Dermatology
- Vol. 30 (4) , 494-495
Shock Treatment: Swimming Pool Contact Dermatitis
Allergic contact dermatitis to potassium peroxymonosulfate, used as a chemical shock treatment for hot tubs and swimming pools, should be in the differential diagnosis for patients presenting with dermatitis triggered by swimming pool or hot tub exposure. We report the first pediatric case of allergic contact dermatitis to potassium peroxymonosulfate after swimming exposure.
- 7 November 2012
- Published by Wiley in Pediatric Dermatology
- Vol. 30 (4) , 494-495
Shock Treatment: Swimming Pool Contact Dermatitis
Allergic contact dermatitis to potassium peroxymonosulfate, used as a chemical shock treatment for hot tubs and swimming pools, should be in the differential diagnosis for patients presenting with dermatitis triggered by swimming pool or hot tub exposure. We report the first pediatric case of allergic contact dermatitis to potassium peroxymonosulfate after swimming exposure.
- 20 September 2012
- Published by Wiley in Pediatric Dermatology
- Vol. 30 (1) , 71-89
Propranolol Use in PHACE Syndrome with Cervical and Intracranial Arterial Anomalies: Collective Experience in 32 Infants
The objective of this retrospective study of patients evaluated between July 2008 and October 2011 in seven pediatric dermatology centers was to combine collective clinical experience using oral propranolol therapy in 32 infants with PHACE syndrome (Posterior fossa [brain malformations present at birth], Hemangioma [usually covering a large area of the skin of the head or neck >5 cm]; Arterial lesions [abnormalities of the blood vessels in the neck or head]; Cardiac abnormalities or aortic coarctation [abnormalities of the heart or blood vessels that are attached to the heart]; Eye abnormalities) with cervical or intracranial arterial anomalies. Patients were given an average daily dose of oral propranolol of 1.8 mg/kg divided two or three times per day for an average duration of 12.3 months. The main outcome measure was adverse neurologic events. Seven (22%) patients were categorized as being at higher risk for stroke, defined on magnetic resonance imaging as severe, long‐segment narrowing or nonvisualization of major cerebral or cervical vessels without anatomic evidence of collateral circulation, often in the presence of concomitant cardiovascular comorbidities. Only one patient developed a change in neurologic status during propranolol treatment: mild right hemiparesis that remained static and improved while propranolol was continued. An additional three patients had worsening hemangioma ulceration or tissue necrosis during therapy. This is the largest report thus far of patients with PHACE syndrome treated with propranolol. Although no catastrophic neurologic events occurred, serious complications, particularly severe ulcerations, were seen in a minority of patients, and given the sample size, we cannot exclude the possibility that propranolol could augment the risk of stroke in this population. We propose radiologic criteria that may prove useful in defining PHACE patients as being at high or standard risk for stroke. We continue to advise caution in using systemic beta‐blockers, particularly for children with vascular anomalies at higher risk for stroke. Use of the lowest possible dosage, slow dosage titration, three times per day dosing to minimize abrupt changes in blood pressure, and close follow‐up, including neurologic consultation as needed, are recommended.
- 20 September 2012
- Published by Wiley in Pediatric Dermatology
- Vol. 30 (1) , 71-89
Propranolol Use in PHACE Syndrome with Cervical and Intracranial Arterial Anomalies: Collective Experience in 32 Infants
The objective of this retrospective study of patients evaluated between July 2008 and October 2011 in seven pediatric dermatology centers was to combine collective clinical experience using oral propranolol therapy in 32 infants with PHACE syndrome (Posterior fossa [brain malformations present at birth], Hemangioma [usually covering a large area of the skin of the head or neck >5 cm]; Arterial lesions [abnormalities of the blood vessels in the neck or head]; Cardiac abnormalities or aortic coarctation [abnormalities of the heart or blood vessels that are attached to the heart]; Eye abnormalities) with cervical or intracranial arterial anomalies. Patients were given an average daily dose of oral propranolol of 1.8 mg/kg divided two or three times per day for an average duration of 12.3 months. The main outcome measure was adverse neurologic events. Seven (22%) patients were categorized as being at higher risk for stroke, defined on magnetic resonance imaging as severe, long‐segment narrowing or nonvisualization of major cerebral or cervical vessels without anatomic evidence of collateral circulation, often in the presence of concomitant cardiovascular comorbidities. Only one patient developed a change in neurologic status during propranolol treatment: mild right hemiparesis that remained static and improved while propranolol was continued. An additional three patients had worsening hemangioma ulceration or tissue necrosis during therapy. This is the largest report thus far of patients with PHACE syndrome treated with propranolol. Although no catastrophic neurologic events occurred, serious complications, particularly severe ulcerations, were seen in a minority of patients, and given the sample size, we cannot exclude the possibility that propranolol could augment the risk of stroke in this population. We propose radiologic criteria that may prove useful in defining PHACE patients as being at high or standard risk for stroke. We continue to advise caution in using systemic beta‐blockers, particularly for children with vascular anomalies at higher risk for stroke. Use of the lowest possible dosage, slow dosage titration, three times per day dosing to minimize abrupt changes in blood pressure, and close follow‐up, including neurologic consultation as needed, are recommended.
- 17 May 2012
- Published by Wiley in Pediatric Dermatology
- Vol. 29 (3) , 363-364
Congenital Nodule on the Scapula
- 17 May 2012
- Published by Wiley in Pediatric Dermatology
- Vol. 29 (3) , 363-364
Congenital Nodule on the Scapula
- 1 August 2010
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 30 (3) , 281-288
Quality-of-life Outcomes and Measurement in Childhood Atopic Dermatitis
- 1 August 2010
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 30 (3) , 281-288
Quality-of-life Outcomes and Measurement in Childhood Atopic Dermatitis
- 1 March 2010
- Published by Wiley in Pediatric Dermatology
- Vol. 27 (2) , 154-155
Oral Sucrose for Pain Relief in Young Infants with Hemangiomas Treated with Intralesional Steroids
Intralesional corticosteroids are one preferred method for treating small localized infantile hemangiomas because of efficacy in halting proliferation and minimal systemic side effects. Although often efficacious, this procedure is uncomfortable for infants. We describe the successful use of an oral 24% sucrose solution given via needleless syringe to the anterior tip of the tongue or in combination with a pacifier as an analgesic during intralesional injection of infantile hemangioma. Options for anesthesia in this young age group include topical prilocaine/lidocaine, injectable lidocaine, and parent soothing. Most often, topical or intralesional anesthesia is deferred when treating hemangiomas of infancy with intralesional corticosteroids. We use oral sucrose as a compassionate option.
- 1 March 2010
- Published by Wiley in Pediatric Dermatology
- Vol. 27 (2) , 154-155
Oral Sucrose for Pain Relief in Young Infants with Hemangiomas Treated with Intralesional Steroids
Intralesional corticosteroids are one preferred method for treating small localized infantile hemangiomas because of efficacy in halting proliferation and minimal systemic side effects. Although often efficacious, this procedure is uncomfortable for infants. We describe the successful use of an oral 24% sucrose solution given via needleless syringe to the anterior tip of the tongue or in combination with a pacifier as an analgesic during intralesional injection of infantile hemangioma. Options for anesthesia in this young age group include topical prilocaine/lidocaine, injectable lidocaine, and parent soothing. Most often, topical or intralesional anesthesia is deferred when treating hemangiomas of infancy with intralesional corticosteroids. We use oral sucrose as a compassionate option.
- 1 May 2009
- Published by Wiley in Pediatric Dermatology
- Vol. 26 (3) , 247-256
What Is “High Risk?” A Systematic Review of Atopy Risk and Implications for Primary Prevention
Abstract: Atopic diseases are common and becoming more prevalent. Efforts have focused on primary disease prevention by identifying high‐risk children and applying preventative strategies. Our aim was to evaluate methods used to identify high‐risk children in atopy prevention studies. A literature search for relevant articles published between 1986 and 2006 was conducted, and all abstracts were reviewed. The search yielded 1,535 publications, 133 were reviewed in detail, and 57 met inclusion criteria. High risk was defined by 30 different methods. First‐degree relatives with an atopic disorder were included in all methods, but only three publications used referenced questionnaires to determine this. Less frequently included were cord blood immunoglobulin E measurements and skin prick or radioallergosorbent testing, and 16 methods relied on history alone. Family history was the most common method used to predict high risk of atopic disease in a child, but a minority of studies used a tested questionnaire to determine the presence of atopy in family members. The methods used to identify high‐risk children are variable, and the development and widespread use of a validated, practical screening tool is needed.
- 1 May 2009
- Published by Wiley in Pediatric Dermatology
- Vol. 26 (3) , 247-256
What Is “High Risk?” A Systematic Review of Atopy Risk and Implications for Primary Prevention
Abstract: Atopic diseases are common and becoming more prevalent. Efforts have focused on primary disease prevention by identifying high‐risk children and applying preventative strategies. Our aim was to evaluate methods used to identify high‐risk children in atopy prevention studies. A literature search for relevant articles published between 1986 and 2006 was conducted, and all abstracts were reviewed. The search yielded 1,535 publications, 133 were reviewed in detail, and 57 met inclusion criteria. High risk was defined by 30 different methods. First‐degree relatives with an atopic disorder were included in all methods, but only three publications used referenced questionnaires to determine this. Less frequently included were cord blood immunoglobulin E measurements and skin prick or radioallergosorbent testing, and 16 methods relied on history alone. Family history was the most common method used to predict high risk of atopic disease in a child, but a minority of studies used a tested questionnaire to determine the presence of atopy in family members. The methods used to identify high‐risk children are variable, and the development and widespread use of a validated, practical screening tool is needed.
- Open Access
- 1 June 2007
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 143 (6) , 768-772
Childhood Atopic Dermatitis Impact Scale
Atopic dermatitis (AD) is an extremely prevalent disease that affects 7% to17% of school-aged children in the United States1 and has well-documented effects on quality of life (QOL).2 In young children with AD, QOL is impaired owing to pruritus, sleep disturbance, pain, irritability, fussiness, restricted activities, and adverse social interactions. In addition, parents of children with AD experience sleep disturbance, exhaustion, frustration, and worry owing to their child's disease.2-8 These and other effects on both the child and parent can be measured with comprehensive QOL scales. Published scales for this purpose include the Children's Dermatology Life Quality Index, the Dermatitis Family Impact Scale, the Infants' Dermatitis Quality of Life Index, and the Parents' Index of Quality of Life for Atopic Dermatitis.9-12
- 1 June 2007
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 143 (6) , 768-772
Open AccessChildhood Atopic Dermatitis Impact Scale
Atopic dermatitis (AD) is an extremely prevalent disease that affects 7% to17% of school-aged children in the United States1 and has well-documented effects on quality of life (QOL).2 In young children with AD, QOL is impaired owing to pruritus, sleep disturbance, pain, irritability, fussiness, restricted activities, and adverse social interactions. In addition, parents of children with AD experience sleep disturbance, exhaustion, frustration, and worry owing to their child's disease.2-8 These and other effects on both the child and parent can be measured with comprehensive QOL scales. Published scales for this purpose include the Children's Dermatology Life Quality Index, the Dermatitis Family Impact Scale, the Infants' Dermatitis Quality of Life Index, and the Parents' Index of Quality of Life for Atopic Dermatitis.9-12
- 1 March 2006
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 19 (2) , 104-107
The psychosocial burden of childhood atopic dermatitis
Atopic dermatitis is an extremely common childhood disease of increasing prevalence that greatly affects the quality of life of afflicted children and of their families. The disease alters the emotional and social functioning of the affected child and their family. The complex multidimensional effects of atopic dermatitis in children and families have been described qualitatively and measured quantitatively with quality of life instruments. Emotional effects on both the child and parents are predominant. The burden of atopic dermatitis can be improved by targeting parents and caregivers with education, psychosocial support, and specialty care.
- 1 March 2006
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 19 (2) , 104-107
The psychosocial burden of childhood atopic dermatitis
Atopic dermatitis is an extremely common childhood disease of increasing prevalence that greatly affects the quality of life of afflicted children and of their families. The disease alters the emotional and social functioning of the affected child and their family. The complex multidimensional effects of atopic dermatitis in children and families have been described qualitatively and measured quantitatively with quality of life instruments. Emotional effects on both the child and parents are predominant. The burden of atopic dermatitis can be improved by targeting parents and caregivers with education, psychosocial support, and specialty care.
- Open Access
- 1 December 2005
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 125 (6) , 1106-1111
Development of the Childhood Atopic Dermatitis Impact Scale: Initial Validation of a Quality-of-Life Measure for Young Children with Atopic Dermatitis and their Families
- 1 December 2005
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 125 (6) , 1106-1111
Open AccessDevelopment of the Childhood Atopic Dermatitis Impact Scale: Initial Validation of a Quality-of-Life Measure for Young Children with Atopic Dermatitis and their Families